Electrostimulation Devices Should Not Be 510(k)-Exempt, Firms Argue
This article was originally published in The Gray Sheet
Executive Summary
FDA should not exempt certain electrostimulation devices and accessories from pre-market submissions due to their "significant safety risks," orthopedic and rehabilitation device firm DJO says
You may also be interested in...
CMS To Scrutinize TENS For Back Pain In National Coverage Analysis
CMS has opened a national coverage analysis for the use of transcutaneous electrical nerve stimulation to treat chronic low back pain, citing a specialty society guideline that concludes the treatment is ineffective.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.